Description
Key facts
Cell type:A-431,
Species or organism:Human,
Tissue:Skin,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 13 bp deletion, 24 bp deletion, 4 bp deletion; Frameshift = 76.79%,
Disease:Epidermoid Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-STK24, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Mammalian Sterile 20-like kinase 3 also known as MST3 or STK24 is a serine/threonine protein kinase with a mass of approximately 49 kDa. MST3 belongs to the STE20 group of kinases which play roles in various cellular processes. It localizes primarily in the cytoplasm and nucleus and sees significant expression in the brain heart liver and skeletal muscles. MST3 also associates with cellular structures such as the Golgi apparatus suggesting a role in intracellular transport or signaling.
Biological function summary
MST3 participates in regulating cell proliferation apoptosis and migration. It is not part of a larger complex but works closely with other signaling proteins to influence these processes. MST3 impacts cytoskeletal organization contributing to the dynamic remodeling of actin filaments. This protein also affects the apoptotic pathways by modulating the interactions with other kinases and apoptosis-related factors thereby aiding in the maintenance of cellular homeostasis.
Pathways
MST3 plays significant roles in the Hippo signaling pathway and the MAPK pathway—both critical for cell growth survival and differentiation. MST3 shares pathways with kinases like MOB1 and NDR1/2 in the Hippo pathway where it assists in regulating cell proliferation and apoptosis. In the context of MAPK signaling MST3 interacts with and is regulated by RAF1 and MEK1/2 coordinating cell stress responses and signaling cascades.
MST3 has associations with neurological disorders and cancer. In the context of neurological disorders MST3 activity affects neuronal apoptosis and tau phosphorylation processes that relate to neurodegenerative diseases. In cancer biology MST3 regulates apoptosis and proliferation and its dysregulation might contribute to tumorigenesis. MST3 connects with proteins such as BCL2 and PARP1 that also influence these disease states making it a protein of interest for therapeutic research.
